2:10 PM
 | 
May 16, 2018
 |  BC Extra  |  Company News

Priority Review for Insmed’s ALIS in rare lung infection

Insmed Inc. (NASDAQ:INSM) said FDA accepted and granted Priority Review to an NDA for ALIS (amikacin liposome inhalation suspension) to treat non-tuberculous mycobacterial lung disease caused by Mycobacterium avium complex (MAC). The PDUFA date is Sept. 28.

The company said it expects an advisory committee meeting to discuss the NDA.

Last September, Insmed reported ALIS met the primary endpoint in a Phase III trial in the indication (see BioCentury Extra, Sept. 5, 2017).

Insmed gained $0.69 to $27.89 on Wednesday.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD